Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-813-0 | CAS number: 110-89-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
Additional information
Absorption:
In a secondary source publication (original data not available) piperidine was reported to be absorbed from the respiratory tract, digestive tract, and skin (Gehring, 1983, cited in NAC/AEGL Committee, ACUTE EXPOSURE GUIDELINE LEVELS (AEGLs) for piperidine (CAS No. 110-89-4) 2007).
Accordingly, Zaeva et al. (1968, original publication in Russian, cited in BG Chemie, Toxicological evaluation No 72 Piperidine, 2000) found that after immersion of the tail of mice the test item was well absorbed through the skin and the amount was sufficient to cause death of the animals with a median lethal time of 77 minutes.
Absorption via the respriratory route and the gastrointestinal tract is supported by pronounced oral and inhalative toxicity (see Chapter 7.2.1).
Distribution:
Piperidine was reported to be detected in various organs of mammalian and non-mammalian species (reviewed in Giacobini 1976 and Kasé 1976, see Chapter 7.10.1 and 7.12). It has been identified in muscle, liver, heart, kidney, spleen, testes, small intestine, lung of rats and mice. In healthy humans piperidine was found in heart, kidneys, liver, and cerebrospinal fluid. The highest concentrations were found in the brain.
Metabolism:
Piperidine is a normal human metabolic product. In mammalians piperidine is synthesized in and outside of the brain. Thereby, piperidine is synthesized endogenously from lysine, cadaverine, and pipecolic acid. There are two possible biosynthetic pathways using the amino acid lysine as basic product (reviewed in Giacobini 1976, see Chapter 7.10.1). In the brain, it seems to be obvious that piperidine is derived from lysine, either exogenously or endogenously, by two alternative routes. One pathway via cadaverine, the decarboxylation product of lysine, involving deamination and cycIization of cadaverine. The other pathway from lysine, via pipecolic acid as an intermediate step, and decarboxylation. So homogenates of brain tissue are proved to convert pipecolic acid to piperidine. After intraperitoneal injection of radioactive pipecolic acid, radioactive piperidine is recovered from rat brain.
Piperidine is N-oxidized to the corresponding N-Hydroxylamine. Other metabolites are 2,3,4,5 -tetrahydropyridine-1 -oxide, 3 -hydroxy piperidine, 4 -hydroxy piperidine and Piperidone-2 (Wang et al., 1989 and Okano et al., 1978).
Excretion:
Piperidine is excreted by the kidneys. Okano et al., (1978) found unchanged piperidine, 3-hydroxypiperidine, 4-hydroxypiperidine, and two unidentified metabolites in urine collected over 72 hours after i.p. injection of rats with [³H]piperidine. Using a colorimetric method, von Euler (1945) investigated the amount of piperidine in the urine of non-smoking human subjects. In total male subjects excreted 8.5 mg and females 7.6 mg in 24-hours.
Mechanism of toxicity:
Piperidine is a very strong alkaline agent with a pKb of 2.88 at 25°C. It is therefore severely corrosive to skin and causes burns to the skin after less than 3 min exposure duration (Linch, 1965, see Chapter 7.10.3). Due to the corrosive property, piperidine causes also severe eye damage and is expected to cause irritation to the respiratory tract (see Chapter 7.3).
Piperidine occurs naturally in the brain and in other tissues of vertebrates and invertebrates. It is proved as a biogenic amine and acts as a neuromodulator (Giacobini, 1976, see Chapter 7.10.1 and 7.12). Thus piperidine effects respiration, blood pressure, contraction of smooth muscle and skeletal muscle (Kasé 1976 see Chapter 7.10.1 and 7.12). Additionally, piperidine acts on the central nervous system and mimics nicotinic effects (reviewed in Giacobini, 1976, see Chapter 7.10.1 and 7.12).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.